For: | Huang CH, Amodio P. Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment? World J Hepatol 2024; 16(2): 115-119 [PMID: 38495281 DOI: 10.4254/wjh.v16.i2.115] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v16/i2/115.htm |
Number | Citing Articles |
1 |
Jie Cheng, Guo-Xin Sun, Li-Ying Cai, Qi-Qun Tang. Exploring pathogenic mechanism and nutritional treatment strategies for hepatic encephalopathy based on the gut-liver axis theory. World Chinese Journal of Digestology 2024; 32(11): 793 doi: 10.11569/wcjd.v32.i11.793
|
2 |
Hideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kyoko Hoshikawa, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Kazuhiko Koike, Hitoshi Yoshiji. Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. Journal of Clinical Medicine 2025; 14(4): 1358 doi: 10.3390/jcm14041358
|
3 |
Elena Fasniuc-Pereu, Elena Niculina Drăgoi, Dumitru Bulgariu, Maria-Cristina Popescu, Laura Bulgariu. Removal of Rifampicin and Rifaximin Antibiotics on PET Fibers: Optimization, Modeling, and Mechanism Insight. Polymers 2025; 17(15): 2089 doi: 10.3390/polym17152089
|